Medtronic has unveiled MiniMed as the official name of its upcoming diabetes spin-off, paying tribute to the original brand it acquired in 2001.
Key Highlights:
- The new standalone company will include 8,000+ employees and is expected to launch within 18 months.
- MiniMed aims to go public via an IPO, followed by a split-off from Medtronic.
- Medtronic CEO Geoff Martha said the move allows sharper focus on high-margin, core growth areas.
- Que Dallara, current president of the diabetes division, will lead MiniMed as CEO.
- The brand honors the legacy of founder Alfred E. Mann, whose innovations helped transform diabetes care since 1983.
“We’ll focus relentlessly on making diabetes more predictable so everyone can embrace life to the fullest,” said Dallara.
Follow MEDWIRE.AI for updates on medtech spinoffs and diabetes innovation.
